Poltreg S.A.

Warsaw Stock Exchange PTG.WA

Poltreg S.A. Capital Expenditure for the year ending December 31, 2023: USD -8.01 M

Poltreg S.A. Capital Expenditure is USD -8.01 M for the year ending December 31, 2023, a -362.60% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Poltreg S.A. Capital Expenditure for the year ending December 31, 2022 was USD -1.73 M, a -135.80% change year over year.
Poltreg S.A. Capital Expenditure for the year ending December 31, 2021 was USD -733.98 K, a 0.00% change year over year.
Poltreg S.A. Capital Expenditure for the year ending December 31, 2020 was USD 0.00, a 100.00% change year over year.
Poltreg S.A. Capital Expenditure for the year ending December 31, 2019 was USD -110.78 K, a -302.90% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Warsaw Stock Exchange: PTG.WA

Poltreg S.A.

CEO	Mr. Piotr Trzonkowsk
IPO Date	Nov. 23, 2021
Location	Poland
Headquarters	Waly Piastowskie 1 lok. 1508
Employees	25
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.

Key trends

Past 5 years